Targeting Specific Immunologic Pathways in Crohn's Disease

Guilherme Piovezani Ramos, William Alvis Faubion, Konstantinos Papadakis

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Understanding the immunologic pathways in intestinal inflammation is crucial for the development of new therapies that can maximize patient response and minimize toxicity. Targeting integrins and cytokines is intended to control leukocyte migration to effector sites or inhibit the action of proinflammatory cytokines. New approaches to preventing leukocyte migration may target integrin receptors expressed on the intestinal vascular endothelium. The IL-12/IL-23 pathway has been a therapeutic target of interest in controlling active Crohn disease (CD). New therapeutic approaches in CD may involve the enhancement of antiinflammatory cytokine pathways, and modulation of cellular responses and intranuclear signals associated with intestinal inflammation.

Original languageEnglish (US)
JournalGastroenterology Clinics of North America
DOIs
StateAccepted/In press - 2017

Fingerprint

Crohn Disease
Cytokines
Integrins
Leukocytes
Inflammation
Interleukin-23
Vascular Endothelium
Interleukin-12
Anti-Inflammatory Agents
Therapeutics

Keywords

  • Crohn's disease
  • Immunology
  • Inflammatory bowel diseases
  • Target therapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{e52d7bbb808c4696b2fbdd9cfb21568d,
title = "Targeting Specific Immunologic Pathways in Crohn's Disease",
abstract = "Understanding the immunologic pathways in intestinal inflammation is crucial for the development of new therapies that can maximize patient response and minimize toxicity. Targeting integrins and cytokines is intended to control leukocyte migration to effector sites or inhibit the action of proinflammatory cytokines. New approaches to preventing leukocyte migration may target integrin receptors expressed on the intestinal vascular endothelium. The IL-12/IL-23 pathway has been a therapeutic target of interest in controlling active Crohn disease (CD). New therapeutic approaches in CD may involve the enhancement of antiinflammatory cytokine pathways, and modulation of cellular responses and intranuclear signals associated with intestinal inflammation.",
keywords = "Crohn's disease, Immunology, Inflammatory bowel diseases, Target therapy",
author = "Ramos, {Guilherme Piovezani} and Faubion, {William Alvis} and Konstantinos Papadakis",
year = "2017",
doi = "10.1016/j.gtc.2017.05.009",
language = "English (US)",
journal = "Gastroenterology Clinics of North America",
issn = "0889-8553",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Targeting Specific Immunologic Pathways in Crohn's Disease

AU - Ramos, Guilherme Piovezani

AU - Faubion, William Alvis

AU - Papadakis, Konstantinos

PY - 2017

Y1 - 2017

N2 - Understanding the immunologic pathways in intestinal inflammation is crucial for the development of new therapies that can maximize patient response and minimize toxicity. Targeting integrins and cytokines is intended to control leukocyte migration to effector sites or inhibit the action of proinflammatory cytokines. New approaches to preventing leukocyte migration may target integrin receptors expressed on the intestinal vascular endothelium. The IL-12/IL-23 pathway has been a therapeutic target of interest in controlling active Crohn disease (CD). New therapeutic approaches in CD may involve the enhancement of antiinflammatory cytokine pathways, and modulation of cellular responses and intranuclear signals associated with intestinal inflammation.

AB - Understanding the immunologic pathways in intestinal inflammation is crucial for the development of new therapies that can maximize patient response and minimize toxicity. Targeting integrins and cytokines is intended to control leukocyte migration to effector sites or inhibit the action of proinflammatory cytokines. New approaches to preventing leukocyte migration may target integrin receptors expressed on the intestinal vascular endothelium. The IL-12/IL-23 pathway has been a therapeutic target of interest in controlling active Crohn disease (CD). New therapeutic approaches in CD may involve the enhancement of antiinflammatory cytokine pathways, and modulation of cellular responses and intranuclear signals associated with intestinal inflammation.

KW - Crohn's disease

KW - Immunology

KW - Inflammatory bowel diseases

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=85024873144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024873144&partnerID=8YFLogxK

U2 - 10.1016/j.gtc.2017.05.009

DO - 10.1016/j.gtc.2017.05.009

M3 - Article

C2 - 28838416

AN - SCOPUS:85024873144

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

SN - 0889-8553

ER -